These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 34744149)

  • 21. Clinical Implications of Ivabradine in the Contemporary Era.
    Imamura T
    Medicina (Kaunas); 2024 Feb; 60(2):. PubMed ID: 38399590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients.
    Reil JC; Tardif JC; Ford I; Lloyd SM; O'Meara E; Komajda M; Borer JS; Tavazzi L; Swedberg K; Böhm M
    J Am Coll Cardiol; 2013 Nov; 62(21):1977-1985. PubMed ID: 23933545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heart rate manipulation in dilated cardiomyopathy: Assessing the role of Ivabradine.
    Raja DC; Kapoor A; Sinha A; Kashyap S; Khanna R; Kumar S; Garg N; Tewari S; Goel P
    Indian Heart J; 2018; 70(2):246-251. PubMed ID: 29716702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustained-Release Ivabradine Hemisulfate in Patients With Systolic Heart Failure.
    Ye F; Wang X; Wu S; Ma S; Zhang Y; Liu G; Liu K; Yang Z; Pang X; Xue L; Lu S; Zhong M; Li J; Yu H; Lou D; Cui D; Xie X; Wang J;
    J Am Coll Cardiol; 2022 Aug; 80(6):584-594. PubMed ID: 35926931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Implications of Mitral Valve Inflow Pattern Overlap during Ivabradine Therapy.
    Imamura T; Hori M; Narang N; Besser S; Kinugawa K
    Int Heart J; 2022; 63(1):43-48. PubMed ID: 35095075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ivabradine in Heart Failure: The Representativeness of SHIFT (Systolic Heart Failure Treatment With the IF Inhibitor Ivabradine Trial) in a Broad Population of Patients With Chronic Heart Failure.
    Das D; Savarese G; Dahlström U; Fu M; Howlett J; Ezekowitz JA; Lund LH
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28903983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prescribing patterns to optimize heart rate: analysis of 1,000 consecutive outpatient appointments to a single heart failure clinic over a 6-month period.
    Dierckx R; Cleland JG; Parsons S; Putzu P; Pellicori P; Dicken B; Boyalla V; Clark AL
    JACC Heart Fail; 2015 Mar; 3(3):224-30. PubMed ID: 25650369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of increased dose of diuretics on symptoms, weight, 6-minute walk distance, and echocardiographic measurements of left ventricular systolic and diastolic function in 51 patients with symptomatic heart failure caused by reduced left ventricular ejection fraction treated with beta blockers and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
    Kumar A; Aronow WS; Vadnerkar A; Sivan K; Mittal S
    Am J Ther; 2009; 16(1):5-7. PubMed ID: 19142162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimization of pharmacotherapy in chronic heart failure: is heart rate adequately addressed?
    Franke J; Wolter JS; Meme L; Keppler J; Tschierschke R; Katus HA; Zugck C
    Clin Res Cardiol; 2013 Jan; 102(1):23-31. PubMed ID: 22760479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Limited role for ivabradine in the treatment of chronic heart failure.
    Cullington D; Goode KM; Cleland JG; Clark AL
    Heart; 2011 Dec; 97(23):1961-6. PubMed ID: 21917660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparative Evaluation of -blockers and If-Channel Inhibitor in Patients With Chronic Heart Failure and Preserved Left Ventricular Ejection Fraction].
    Kanorsky SG; Borisenko YV
    Kardiologiia; 2016 Feb; 56(2):24-29. PubMed ID: 28294745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Ivabradine on Cardiac Remodeling in Patients With Stable Symptomatic Heart Failure: A Systematic Review and Meta-analysis.
    Wan H; Huang T; Zhang H; Wu Q
    Clin Ther; 2020 Dec; 42(12):2289-2297.e0. PubMed ID: 33160681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial.
    Colucci WS; Kolias TJ; Adams KF; Armstrong WF; Ghali JK; Gottlieb SS; Greenberg B; Klibaner MI; Kukin ML; Sugg JE;
    Circulation; 2007 Jul; 116(1):49-56. PubMed ID: 17576868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial.
    Komajda M; Isnard R; Cohen-Solal A; Metra M; Pieske B; Ponikowski P; Voors AA; Dominjon F; Henon-Goburdhun C; Pannaux M; Böhm M;
    Eur J Heart Fail; 2017 Nov; 19(11):1495-1503. PubMed ID: 28462519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.
    Kosmala W; Holland DJ; Rojek A; Wright L; Przewlocka-Kosmala M; Marwick TH
    J Am Coll Cardiol; 2013 Oct; 62(15):1330-8. PubMed ID: 23916925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF: Insights From the CIBIS-ELD Trial.
    Edelmann F; Musial-Bright L; Gelbrich G; Trippel T; Radenovic S; Wachter R; Inkrot S; Loncar G; Tahirovic E; Celic V; Veskovic J; Zdravkovic M; Lainscak M; Apostolović S; Neskovic AN; Pieske B; Düngen HD;
    JACC Heart Fail; 2016 Feb; 4(2):140-149. PubMed ID: 26682793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Chronic Heart Failure With Preserved Ejection Fraction: Effective Treatment Possible?].
    Kanorskiy SG; Borisenko YV
    Kardiologiia; 2018 Jun; 58(6):85-89. PubMed ID: 30362441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Ivabradine on Health-Related Quality of Life of Patients with Ischaemic Chronic Heart Failure.
    Sallam M; Al-Saadi T; Alshekaili L; Al-Zakwani I
    Curr Vasc Pharmacol; 2016; 14(5):481-486. PubMed ID: 27145825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT).
    Swedberg K; Komajda M; Böhm M; Borer JS; Ford I; Tavazzi L
    Eur J Heart Fail; 2010 Jan; 12(1):75-81. PubMed ID: 19892778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel drugs for heart rate control in heart failure.
    Bielecka-Dabrowa A; von Haehling S; Rysz J; Banach M
    Heart Fail Rev; 2018 Jul; 23(4):517-525. PubMed ID: 29594814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.